Equities

Solasia Pharma KK

Solasia Pharma KK

Actions
  • Price (EUR)0.2540
  • Today's Change-0.002 / -0.78%
  • Shares traded0.00
  • 1 Year change+4.10%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments728803714
Total Receivables, Net67572126
Total Inventory122140
Prepaid expenses574348
Other current assets, total2.003.006.00
Total current assets9761,435894
Property, plant & equipment, net8163120
Goodwill, net------
Intangibles, net1,1171,5702,079
Long term investments6.0011--
Note receivable - long term------
Other long term assets495551
Total assets2,2293,1343,144
LIABILITIES
Accounts payable--1.00386
Accrued expenses342636
Notes payable/short-term debt000
Current portion long-term debt/capital leases333747
Other current liabilities, total22634320
Total current liabilities293407489
Total long term debt27037
Total debt603784
Deferred income tax225318
Minority interest------
Other liabilities, total121213
Total liabilities354472557
SHAREHOLDERS EQUITY
Common stock1,5961,4362,110
Additional paid-in capital1,6571,5005,738
Retained earnings (accumulated deficit)(1335)(220)(5201)
Treasury stock - common(69)(70)(70)
Unrealized gain (loss)------
Other equity, total261610.00
Total equity1,8752,6622,587
Total liabilities & shareholders' equity2,2293,1343,144
Total common shares outstanding174168134
Treasury shares - common primary issue0.430.440.44
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.